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Abstract
Background: The purpose of this study is to investigate the clinical effects of platelet-rich plasma (PRP) and
adipose-derived mesenchymal stem cell (MSC) as the fundamental treatment of osteoarthritis (OA).
Methods: Twenty four Beagle dogs were used as cranial cruciate ligament transection models. The dogs were divided
into four groups (n = 6) according to the intra-articular injection materials: the control group with phosphate-buffered
saline (PBS), the PRP group with PRP, the MSC group with MSCs emerged in PBS, and the MSC and PRP co-treatment
(MP) group with MSCs and PRP.
Results: Lameness score, focal compression strength, articular extracellular matrix (ECM) compositions, histopathology,
and real-time PCR were used to evaluate the effects of PRP and MSCs on canine OA. In the order of MP, PRP, and MSC
group, these all showed positive effects on the evaluated categories. The lameness scores were lower, and the focal
compression strengths of the affected femoral articular surface cartilages were higher than those in the OA control
group. Also, the inflammatory changes, when evaluated with Mankin scoring and histomorphologic examination, were
significantly ameliorated with the treatment of PRP and/or MSCs. The glycosaminoglycan and collagen composition of
extracellular matrix was more favorable in the test groups. The ECM-related genes significantly increased through the
up-regulation, while the protein expressions of inflammatory cytokines were decreased through the inhibitory effects
of PRP and MSCs on chondrocyte apoptosis and inflammatory cytokines.
Conclusions: Taken together, this study suggests that PRP and MSCs treatments have a beneficial effect on OA via the
stimulation of ECM synthesis and chondrocyte proliferation and via the inhibition of inflammatory reaction.
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Background
Osteoarthritis (OA) is the most common clinical syn-
drome of joint pain and dysfunction, accompanied by
varying degrees of functional limitation and the re-
duced quality of life. Because it is mostly irreversible
and progressive, OA joint consequently loses their
cartilage layer [1].
The most ideal treatment of OA is focused on block-
ing the catabolic activity of cartilage and enhancing re-
generation of normal cartilage. Until now, therapies for
the OA commonly focused on the palliation of pain and
discomfort, improvement on functional movement, and
prevention of further degeneration. Thus, the primary
approach in the clinical treatment of OA involves the
extensive use of NSAIDs, analgesics, and hyaluronan
which allows the brief symptomatic relief but provides
no apparent disease-modifying effect [2–4]. Therefore,
there is a critical need for the development of the alter-
native agents that can fundamentally prevent the de-
struction of cartilages or stimulate its proper repair. In
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these aspects, various efforts have been tried to search
for the effective cartilage-preserving methods with cell
sources.
To sum up, the isolated chondrocyte expansion and
implantation method is regarded as the fundamental so-
lution. However, the main concern of the most cultured
chondrocytes is losing the characteristics of producing
hyaline-like cartilage [5, 6]. In a canine model, it has
been reported that cultured autologous chondrocytes
failed to return to the normal hyaline cartilage [7].
In human, the intra-articular injection of 1.0 × 108 cells
of adipose-derived mesenchymal stem cell (MSC) could
improve the function, reduce the pain, and regenerate
the hyaline-like cartilage [8]. MSCs are typically not ob-
served in synovial fluid. However, MSCs appear in syn-
ovial fluid in the OA condition, and they are thought to
play an important role in the regeneration of damaged
tissue and have anti-inflammatory effect [9]. As the pa-
tient ages, the quality and quantity of MSCs decrease
and there is a reduction of their ability to proliferate and
differentiate. Also, the depletion of healthy MSCs is
regarded as one of the reasons worsening OA [10]. For
these reasons, it is believed that the direct administra-
tion of MSCs could promote the positive role of them
by preventing their depletion and improving cartilage
regeneration [11].
The platelet-rich plasma (PRP) is defined as the plasma
with the platelet population of more than 1.0 × 106
cells/μl, and it has typically four- to eightfold more
platelets than the normal plasma [12]. PRP has vari-
ous growth factors such as platelet-derived growth
factor and transforming growth factor beta [13]. It
has been well known that PRP has angiogenic, anti-
inflammatory, and anti-catabolic effects [13, 14]. It
has also been reported that transforming growth fac-
tor beta and fibroblast growth factor from PRP have
an anabolic effect on cartilage metabolism [15]. These
factors not only regulate the cell migration and prolif-
eration but also enhance the wound healing and
extracellular matrix (ECM) remodeling via the stimu-
lation of angiogenesis [16, 17].
Based on the previous studies, it is hypothesized that
the PRP could have a synergistic effect on the cartilage
regeneration with the combination of MSCs. Therefore,
the purpose of this study is to examine the effect of PRP
and MSCs on the morphologic change and regeneration




Autologous PRP was prepared in each dog using double
spin method. Fifty milliliters of fresh blood was collected
with 7 ml of acid citrate dextrose formula A. Then, the
blood was centrifuged at 1200 rpm for 10 min into three
layers: plasma, buffy coat, and red blood cell. After the
plasma and buffy coat were separated into a new tube,
the mixture was centrifuged at 2500 rpm for 10 min.
Discarding the supernatant, only the lower 20 % of the
plasma was harvested. The collected plasma (PRP) was
tested using complete blood cell count test (Cell-Dyne,
Abbott Lab., USA) to make sure it had 1.0 × 106 plate-
lets/μl or more. All prepared PRP in this study were
used within 6 h.
Adipose-derived mesenchymal stem cell isolation and
culture
Approximately 15 g of fat tissue was aseptically collected
from the flank of a dog. It was rinsed with phosphate-
buffered saline (PBS) several times to remove any
remaining anesthetic agent and blood. Rinsed fat tissue
was then digested using 0.075 % collagenase type I (colla-
genase type 1A, Sigma-Aldrich, USA) in 37 °C water-
chamber for 2 h with shaking or inverting every 30 min.
After adding the equal volumes of Dulbecco modified
Eagle medium and 10 % fetal bovine serum, it was centri-
fuged at 1200 rpm for 10 min. The supernatant and
digested lipids were discarded. The cell pellet was washed
with PBS, and it was filtered through 100-μm nylon mesh.
After centrifuging at the same condition, the cells were
suspended into a 100 × 20 mm cell culture dish with low-
glucose Dulbecco modified Eagle medium and 10 % fetal
bovine serum. After 24 h, non-adherent cells and debris
were washed with PBS, and cell culture media was re-
placed twice per week. MSCs were collected and used be-
tween passage 1 and 2 in all the experiments of this paper.
The flow cytometry analysis with established MSCs was
performed, and obtained MSCs were negative for cluster
of differentiation (CD) 34 and CD45 and strongly positive
for CD29 and CD44 (Additional file 1: Fig. S6).
The canine model of cranial cruciate ligament transection
The procedures were approved by Institutional Animal
Care and Use Committees of Kyungpook National Uni-
versity. Twenty four physically healthy Beagle dogs were
used in this experiment. The weights of dogs were 7.7 ±
1.1 kg (mean ± standard deviation), and ages were
between 2–3 years old. Under the anesthetic state, the
cranial cruciate ligament of a right hind limb was ex-
cised with a no. 11 scalpel blade. The connective tissues
and skin were sutured with routine procedure. Analge-
sics (tramadol 8 mg/kg BID, subcutaneous) and antibi-
otics (enrofloxacin 5 mg/kg SID, subcutaneous) were
administrated for 3 days after the surgery. After a week
for soft tissue healing, each dog regularly walked for
10 min per day for 2 months. Then, treatment was given
every week for 1 month. Another 2 months later, the
dogs were sacrificed and stifle samples were collected.
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MSC and PRP application
After the canine OA model, the subjects were treated
every week for 1 month with an intra-articular injection
with each material according to the groups: the control
group with 1 ml of PBS, the PRP group with 1 ml of
PRP, the MSC group with 1.0 × 107 MSCs in 1 ml of
PBS, and the MSC and PRP co-treatment (MP) group
with 1.0 × 107 MSCs in 1 ml of PRP. The contralateral
stifle joint of the dogs in control group were used as a
sham group in a histopathological examination, and no
treatment material was given.
Evaluations
Lameness score
The lameness score was measured before the surgery
and by every month after the surgery. All dogs had nor-
mal gait and no lameness before surgery. Previously de-
scribed scoring system was used [18], and is as followed:
0, no detectable lameness; 1, minor lateral weight shift
but no lameness at walk and trot; 2, no lameness at a
walk but mild lameness at a trot; 3, mild lameness at a
walk and significant lameness at trot; 4, non-weight
bearing at a trot; and 5, non-weight bearing at walk and
standing. As a blind test, three veterinarians assessed the
grade of lameness.
The measurement of focal compressive strengths
After sacrifice and sampling, the ex vivo compression
strengths of the femoral and tibial articular surfaces
(0.2 mm) of each sample were detected with a comput-
erized testing machine (SV-H1000, Japan Instrumenta-
tion System Co., Tokyo, Japan) as N (Newton). The
measured points were central region of the medial fem-
oral and tibial condyle.
Histological process
The articular cartilages of central region of the lateral
femoral and tibial condyle were taken from knee
joints of each group, and they were separately fixed
in 10 % neutral buffered formalin (NBF), and then
decalcified in decalcifying solution (24.4 % formic acid
and 0.5 N sodium hydroxide) for 14 days (mixed de-
calcifying solution was exchanged once a day for
14 days). Each femoral and tibial articular surface car-
tilage was longitudinally trimmed, then embedded in
paraffin, sectioned (3–4 μm) using tungsten bladder
equipped automated polycut microtome (Model
RM2255, Leica, Wetzlar, Germany), and stained with
Sirius red stain for cartilaginous tissues. In each pre-
pared histological samples, the histological profiles
were interpreted under a light microscope (Model
Eclipse 80i, Nikkon, Tokyo, Japan) as blinds to group
distribution when this analysis was made.
Analysis of ECM compositions
Some parts of the cartilage on the femoral and tibial ar-
ticular surface taken from the knee joints of each group
were separately lyophilized to obtain the dry weight.
Then, the piece was digested and used for glycosamino-
glycan (GAG) and collagen (COL) analyses [19, 20]. The
concentration of GAG was determined through the di-
methyl-methylene blue sulfated GAG assay using a UV/
VIS spectrophotometer (Optizen Pop, Mecasys, Daejeon,
Korea). Collagen content was determined by Erlich’s hy-
droxyproline assay [21]. The hydroxyproline content was
converted to the collagen content using the following
equation: (μg hydroxyproline × dilution factor)/0.13 = μg
collagen, based on the fact that hydroxyproline repre-
senting approximately 13 % of the amino acid content of
collagen in the human meniscus [22]. The concentra-
tions of GAG and collagen were standardized to tissue
dry weight and expressed as microgram per milligram to
allow comparison among the experimental groups.
ECM-related chondrogenic gene mRNA expressions
The SOX9 and aggrecan messenger RNA (mRNA) ex-
pressions on the femoral and tibial articular surface car-
tilages were detected using real-time PCR. Briefly, RNA
was extracted using Trizol reagent (Invitrogen, Carlsbad,
CA, USA). The RNA concentrations and quality were
determined by CFX96™ Real-Time System (Bio-Rad,
Hercules, CA, USA). To remove contaminating DNA,
samples were treated with recombinant DNase I (DNA-
free; Ambion, Austin, TX, USA). RNA was reverse tran-
scribed using the reagent High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. The
cDNA strand was synthesized from the total RNA and
then the mixture of primers and the cDNA products
was amplified by PCR, and the conditions of PCR ampli-
fication were 58 °C for 30 min, 94 °C for 2 min, 35 cycles
of 94 °C for 15 s, 60 °C for 30 s, 68 °C for 1 min, and
then 72 °C for 5 min. Analysis was carried out using ABI
Step One Plus Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA), and their expression
levels were calculated as relative to sham group. The
expression of glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) mRNA was used as a control for tissue integ-
rity in all of the samples. The sequences of the PCR
oligonucleotide primers were as listed in Table 1.
BrdU uptake measurement
To assess the effects of MSC and PRP or their co-
treatment (MP) on the proliferation of cells within the
dog knee joints, proliferating cells were labeled by an
intraperitoneal injection of 5-bromo-2′-deoxyuridine
(BrdU). Dogs were given intraperitoneal injections of
BrdU (Sigma-Aldrich, St. Louise, MO, USA) 50 mg/kg,
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in a volume of 1 ml/kg and dissolved in saline, and the
animals were sacrificed 72 h later. BrdU uptakes were
detected with immunohistochemistry using an anti-
BrdU antibody, as shown in histomorphometry sections.
Immunohistochemistry
Immunoreactivity for BrdU as cell proliferating marker
was considered using purified primary antibody with
avidin-biotin-peroxidase complex (ABC). Immunoreactiv-
ities in the prepared femoral and tibial surface cartilage
tissues against caspase-3, cleaved poly(ADP-ribose) poly-
merase (PARP), tumor necrosis factor (TNF)-α, cyclooxy-
genase (COX)-2, interleukin (IL)-1β, interferon (IFN)-γ,
and inducible nitric oxide synthase (iNOS) were also add-
itionally observed after treatment MSCs, PRP, or their
combination. Briefly, endogenous peroxidase activity was
blocked by incubated in methanol and 0.3 % H2O2 for
30 min, and non-specific binding of immunoglobulin was
blocked with normal horse serum blocking solution for
1 h in humidity chamber after epitope retrievals by pre-
treatment of trypsin (Sigma-Aldrich, St. Louise, MO,
USA) and 2 N HCl, on the prepared unstained sections.
The primary antisera were treated for overnight at 4 °C in
humidity chamber and then incubated with biotinylated
universal secondary antibody and ABC reagents for 1 h at
room temperature in humidity chamber. Finally, sections
were reacted with peroxidase substrate kit for 3 min at
room temperature. All sections were rinse in 0.01 M PBS
for three times, between each step. The primary antisera
and detection kits for immunohistochemistry used in this
study were described in Additional file 1: Table S1.
Histomorphometry
To observe more detailed histopathological changes, the
articular cartilage injuries stained with Safranin O stain-
ing were evaluated and recorded using the Mankin scor-
ing systems referred by the other studies [23]. With this
system, the higher the score, the higher the level of OA
(semiquantative scores; max = 12). The thicknesses of
femur and tibia articular cartilages (micrometer per car-
tilage) were measured with the histomorphometrical
analyses at prepared longitudinally trimmed samples,
using a computer based automated image analyzer
(iSolution FL ver 9.1, IMT i-solution Inc., Vancouver,
Quebec, Canada). A total of six histological regions of
femoral and tibial articular surface regions of each
group were considered for further analysis. The cells
occupied by over 20 % of immunoreactivities, the
density, of each antibody for caspase-3, PARP, TNF-α,
COX-2, IL-1β, IFN-γ, and iNOS were regarded as
positive, and the numbers of each immunoreactive
cells were counted separately in each of the femoral
and tibial articular surface regions as cells per square
millimeter, under blinds condition.
Statistical analysis
The values were expressed as mean ± standard deviation
(SD). A multiple comparison tests were conducted for
different groups. According to the result of variance
homogeneity by the Levene test, one-way ANOVA test
and the least-significant differences (LSD) multi-
comparison test were used for parametric comparison,
and Kruskal-Wallis H test was used for non-parametric
comparisons, followed by Mann-Whitney (MW) U test
with Bonferroni correction. Statistical analyses were con-
ducted using SPSS for Windows (Release 14.0K, IBM
SPSS Inc., USA).
Results
Although the lameness score in MP group was de-
creased compared to those in the other groups, there
were no significant changes between groups. The lame-
ness score was significantly decreased at 2 months and
at 3 months after treatment in the PRP group and MP
group when compared with the previous treatment,
respectively (Fig. 1).
The focal compressive strength of the femoral and
tibial articular surface cartilages were significantly de-
creased in the control group as compared to that of
the sham group. However, the focal compressive
strength significantly increased by the treatment of all
three test materials. In MP group, the focal compres-
sive strength was higher than those in any other
treated groups (Fig. 2).
The Mankin scores of control group were significantly
increased as compared with those of shame group.
When compared with control group, it was found that
the Mankin score significantly reduced with the treat-
ment of all three test materials on the femoral and tibial
articular cartilages. Especially, the Mankin score of MP
treated dogs was lowest compared to those of MSC or
PRP treated dogs (Table 2).
The thickness of articular cartilages was higher in
the MSC and PRP than control group. The more fa-
vorable effect on the articular surface was examined
Table 1 Oligonucleotides for real-time PCR used in this study
Target 5′–3′ Sequence NCBI accession
no.
SOX9 Sense AAGCTCTGGAGGCTGCTGAA NM_001002978.1
Antisense ACTTGTAATCCGGGTGGTCTTTC
Aggrecan Sense CTATGAGGACGGCTTTCACC U65989.2
Antisense AGACCTCACCCTCCATCTCC
G3PDH Sense TATTGTCGCCATCAATGACC NM_01003142
Antisense TACTCAGCACCAGCATCACC
PCR polymerase chain reaction, NCBI National Center for
Biotechnology Information
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Fig. 1 The lameness score of the OA dogs. Control, treated with 1 ml of PBS; PRP, treated with 1 ml of PRP; MSC, treated with 1.0 × 107 MSC in
1 ml of PBS; MP, treated with 1.0 × 107 MSC cell in 1 ml of PRP. Asterisk indicates significantly different with day 0 within PRP group by MW test;
Number sign significantly different with day 0 within MP group by MW test
Fig. 2 Focal compressive strengths on the femoral and tibial articular cartilages. Values are expressed as mean ± SD of six dogs, N (Newton). ap < 0.05
as compared with sham control by LSD test; bp < 0.05 as compared with control by LSD test; cp < 0.05 as compared with MSC treated group by LSD
test; dp < 0.01 and ep < 0.05 as compared with PRP treated group by LSD test
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Table 2 Mankin scores on the femur and tibia articular cartilages
Groups Femur Tibia
Surface damage Hypocellularity Clone Stain intensity Totalized (max = 12) Surface damage Hypocellularity Clone Stain intensity Totalized (max = 12)
Sham 0.33 ± 0.52 0.17 ± 0.41 0.17 ± 0.41 0.33 ± 0.52 1.00 ± 0.63 0.17 ± 0.41 0.33 ± 0.52 0.17 ± 0.41 0.17 ± 0.41 0.83 ± 1.60
Control 2.50 ± 0.55a 1.67 ± 0.52a 1.33 ± 0.82a 1.67 ± 0.52a 7.17 ± 1.17a 2.17 ± 0.41a 2.17 ± 0.41a 1.00 ± 0.63a 1.50 ± 0.55a 6.83 ± 1.17a
MSC 1.00 ± 0.63bc 0.83 ± 0.41bc 1.17 ± 0.41a 1.17 ± 0.41b 4.17 ± 0.75ac 0.67 ± 0.52c 1.17 ± 0.41bc 0.67 ± 0.52 1.33 ± 0.52a 3.83 ± 0.75ac
PRP 0.83 ± 0.41c 0.83 ± 0.41bc 0.83 ± 0.41b 1.00 ± 0.00 3.50 ± 0.55ac 0.50 ± 0.55c 0.83 ± 0.75c 0.67 ± 0.52 1.17 ± 0.41a 3.17 ± 0.98ac
MP 0.50 ± 0.55c 0.33 ± 0.52c 0.33 ± 0.52cf 0.33 ± 0.52cf 1.50 ± 1.38ceg 0.33 ± 0.52c 0.33 ± 0.52cf 0.17 ± 0.41c 0.50 ± 0.55ceh 1.33 ± 1.21ceh
Values are expressed as mean ± SD of six dogs
MSC mesenchymal stem cells, PRP platelet-rich plasma, MP MSC and PRP co-treatment
ap < 0.01 as compared with sham control by LSD test
bp < 0.05 as compared with sham control by LSD test
cp < 0.01 as compared with control by LSD test
dp < 0.05 as compared with control by LSD test
ep < 0.01 as compared with MSC treated group by LSD test
fp < 0.05 as compared with MSC treated group by LSD test
gp < 0.01 as compared with PRP treated group by LSD test














in MP group, compared to those of MSC and PRP
groups (Fig. 3).
The contents of COL and GAG as the main compo-
nent of ECM were significantly decreased in control
group compared with those of sham group, but it was
significantly increased in all treated groups compared
with control group (Fig. 4).
When the real-time PCR performed to determine the
ECM-related genes, the expression of cartilage aggrecan
and SOX9 was decreased as compared with those of
sham group. However, those down-regulated gene ex-
pressions were significantly increased by the treatment
of all three test materials, and it was most potent in MP
group (Fig. 5).
The BrdU-positive cells in the femoral and tibial ar-
ticular cartilages significantly decreased in control group
comparing to that of sham group. The values were sig-
nificantly increased in all treated groups compared with
control group. The increase of cell proliferation on the
cartilage was most significant in MP group than MSC or
PRP group (Fig. 6, Tables 3 and 4).
Immunopositive cells to caspase-3 and PARP were sig-
nificantly increased in the femoral and tibial cartilages of
control group when compared with those of the sham
Fig. 3 Representative general histopathological images and the thicknesses of the femoral and tibial articular cartilages. Of sham (a, b), control
(c, d), MSC (e, f), PRP (g, h), and MP (i, j). H&E and Safranin O stain. Scale bars = 90 μm. ap < 0.01 as compared with sham control by LSD test;
bp < 0.01 and cp < 0.05 as compared with control by LSD test; dp < 0.01 as compared with MSC treated group by LSD test; ep < 0.01 and fp < 0.05
as compared with PRP treated group by LSD test
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group. However, these increased cells were significantly
reduced by treatment of all three test materials, and the
reduction was most significant in MP group (Fig. 6,
Tables 3 and 4).
TNF-α, COX-2, IL-1β, iNOS, and IFN-γ staining cells
were increased significantly in the femoral and tibial car-
tilages of control group compared with sham group.
However, these increases of pro-inflammatory cytokines
on the cartilages were diminished in treated groups
(Fig. 6 and Additional file 1: Fig. S1-S5, Tables 3 and 4).
Discussion
Osteoarthritis (OA) is characterized by the loss of articu-
lar cartilage components with inflammation, eventually
resulting in impaired joint function [24, 25]. For this rea-
son, this study mainly focused on the evaluation of the
clinical signs, the change of ECM component and articu-
lar cartilage, the gene expression related to chondrogen-
esis, and the articular pathologic processes such as
inflammation and apoptosis with the treatment of PRP
and/or MSC.
Previously, it has been reported that the intra-articular
injection of PRP reduced the lameness score [26]. Simi-
larly, there were a meaningful decrease of lameness
score with the treatment of PRP and MSC mixed with
PRP in this canine OA model. Based on this result, we
anticipate that PRP would relieve pain and improve
articular function in an arthritic condition.
It is well known that the structure of articular cartilage
is altered by the disorganization of collagen network, de-
crease of proteoglycan contents, and disruption of the
integrity of the ECM in the process of OA [27]. There-
fore, we tested the compressive strength of the articular
cartilage to observe whether PRP or MSCs has a protect-
ive effect on the articular damage by OA. As previous
studies have reported, Mankin score is a good index of
osteoarthritis [28] and it is highly associated with com-
pressive strength of articular cartilage [27]. We evaluated
Fig. 4 COL and GAG contents on the femoral articular cartilages. ap < 0.01 as compared with sham control by LSD test; bp < 0.01 and cp < 0.05 as
compared with control by LSD test; dp < 0.01 as compared with MSC treated group by LSD test; ep < 0.01 and fp < 0.05 as compared with PRP
treated group by LSD test
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Mankin score of the affected articular cartilage. In
addition, the thickness of articular cartilage and the con-
tent of COL and GAG were measured to confirm the
OA condition. As a result, there were decreases in
Mankin score as well as increases in the thickness of
cartilage and the content of COL and GAG in the
PRP and/or MSC treatment. These results suggested
that PRP and MSC may have protective and regenera-
tive effects on the degenerative cartilage of OA.
Aggrecan is known as a core protein of cartilage-
specific proteoglycan, and it was reported that the
mRNA expression of aggrecan was down-regulated ac-
cording to the severity of OA condition [29, 30]. The ex-
pression of SOX9, the essential transcription factor for
the chondrogenic differentiation, was also inhibited by
OA model [30]. In this study, the down-regulations of
SOX-9 and aggrecan in the control group were increased
by the MSC and PRP treatment. Based on these results,
we can suppose that the increase of ECM-related factors
such as aggrecan, SOX9, COL, and GAG may be closely
associated with the recovery of damaged articular cartil-
age. From this aspect, it could be explained by the fact
that PRP and/or MSC treatment was associated with the
increase of focal compressive strengths and the decrease
of Mankin score. These findings are compatible with a
previous report indicated that the inhibition of SOX9
gene expression and the content of GAG might result in
cartilage degeneration [30].
We next performed BrdU staining to examine whether
the MSC and/or PRP treatment promoted the prolifera-
tion of chondrocytes. It was shown that BrdU-positive
cells decreased in OA condition and increased with a
treatment of MSC and/or PRP. We also performed im-
munostaining for the caspase-3 and PARP expression
examine whether apoptotic change during OA could be
affected by PRP and/or MSC treatment. Results showed
that the number of caspase-3- and PARP-positive cells
was increased in the OA condition and was reduced
Fig. 5 mRNA expressions of aggrecan and SOX9 on the femoral and tibial articular cartilages. Values are expressed as mean ± SD of six dogs,
relative to control/G3PDH mRNA. ap < 0.01 and bp < 0.05 as compared with sham control by LSD test; cp < 0.01 and dp < 0.05 as compared with
control by LSD test; ep < 0.01 as compared with MSC treated group by LSD test; fp < 0.01 and gp < 0.05 as compared with PRP treated group by
LSD test
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with a treatment of MSC and/or PARP. These results
were consistent with the findings of previous study that
caspase-3 led to PARP to cleavage and consequently
caused the progression of OA with cell apoptosis and
death [31]. Therefore, we propose that the proliferation
of chondrocyte may be suppressed in the process of OA
through apoptotic change of articular cartilage, and this
may be partly prevented by MSC and/or PRP treatment.
We examined the protein expression of cytokines rela-
tive to inflammatory reaction in the cartilage tissue. It
has been known that pro-inflammatory cytokines medi-
ated the activation of various inflammatory pathways
and played a role in the progression of OA [32]. In the
present study, the numbers of TNF-α-, COX-2-, IL-1β-,
IFN-γ-, and iNOS-positive cells were increased in the
OA condition, and MSC and/or PRP treatment
Fig. 6 Representative immunohistochemical findings of femoral and tibial articular cartilage (BrdU, TNF-α, and PARP). Of sham (a, b), control
(c, d), MSC (e, f), PRP (g, h), and MP (i, j). Scale bars = 90 μm
Table 3 Immunohistochemical analysis on the femur articular cartilages
Cell numbers (cells/mm2) Sham Control MSC PRP MP
BrdU+ 144.17 ± 47.83 9.00 ± 2.83f 55.00 ± 17.34fg 77.17 ± 20.36g 129.67 ± 31.39fghi
IL-1β+ 14.67 ± 4.18 140.50 ± 16.69a 50.83 ± 15.77ab 44.50 ± 13.66ab 23.50 ± 7.87bcd
TNF-α+ 5.50 ± 4.09 103.00 ± 18.70f 55.33 ± 18.91fg 38.00 ± 10.16fg 13.83 ± 3.66ghi
COX-2+ 16.33 ± 2.73 102.67 ± 22.57f 65.50 ± 10.21fg 44.50 ± 10.21fg 23.67 ± 6.92ghi
iNOS+ 57.83 ± 15.82 196.67 ± 42.57a 106.50 ± 17.60ab 66.17 ± 10.53b 40.33 ± 12.40bce
Caspase-3+ 16.50 ± 8.87 80.33 ± 11.22a 52.17 ± 12.62ab 46.17 ± 11.86ab 18.00 ± 8.46bcd
PARP+ 30.00 ± 11.92 101.17 ± 21.64a 64.17 ± 14.63ab 54.50 ± 13.16ab 32.50 ± 10.31bce
IFN-γ+ 5.33 ± 3.27 88.33 ± 13.35a 47.17 ± 11.51ab 31.17 ± 15.28ab 12.50 ± 2.88bcd
Values are expressed as mean ± SD of six dogs
MSC mesenchymal stem cells, PRP platelet-rich plasma, MP MSC and PRP co-treatment
ap < 0.01 as compared with sham control by LSD test
bp < 0.01 as compared with control by LSD test
cp < 0.01 as compared with MSC treated group by LSD test
dp < 0.01 as compared with PRP treated group by LSD test
ep < 0.05 as compared with PRP treated group by LSD test
fp < 0.01 as compared with sham control by MW test
gp < 0.01 as compared with control by MW test
hp < 0.01 as compared with MSC treated group by MW test
ip < 0.01 as compared with PRP treated group by MW test
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stimulated the down-regulated expression of inflamma-
tory cytokines. This result is comparable to the previous
studies that MSC increased the anti-inflammatory cyto-
kines such as IL-10, and PRP also had anti-inflammatory
effect via blockage of NF-κB cascade, which contributes
to the up-regulation of pro-inflammatory cytokines [33].
It has been known that MSC played important role in
the cartilage repair by direct differentiation to chondro-
cyte and paracrine effect [8, 34]. In addition, it also has
been reported that PRP could promote the proliferation
by its various growth factors rather than differentiation
of MSCs [35]. Therefore, PRP might prevent the deple-
tion of MSCs, enhance the effect of MSCs, and guide
MSCs to properly differentiate into chondrocytes. Con-
sistent with previous study, the results of this study
suggested that each treated with either MSC or PRP
could decrease death or apoptosis of chondrocytes and
inhibit inflammatory response [31, 36] and that the co-
treatment with MSC and PRP might have beneficial
effects on the pathologic changes in the articular cartilage.
In summary, we have shown that MSC and/or PRP
ameliorated the degeneration of articular cartilage in
the surgically induced OA animal model. The prolif-
eration of chondrocyte may be suppressed in the
process of OA through apoptotic change of articular
cartilage, and this may be partly prevented by MSC
and/or PRP treatment. MSC and/or PRP treatment
also stimulated the down-regulated expression of in-
flammatory cytokines such as TNF-α-, COX-2-, IL-
1β-, IFN-γ-, and iNOS. It will be needed to elucidate
if transplanted MSCs are engrafted and differentiated
to chondrocyte in OA cartilage and how MSCs and
PRP interact in intra-articular environment.
Conclusions
Taken together, this study shows that the combination of
MSC and PRP has a beneficial and synergistic effect on
OA via the ECM synthesis and chondrocyte proliferation
and via the anti-inflammatory reaction. Therefore, the
combination treatment of MSC and PRP may be very
useful as an inflammatory regulator for the treatment of
OA that exhibit irreversible articular degeneration.
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LSD: least-significant differences; MSC: mesenchymal stem cell;
MW: Mann-Whitney; OA: osteoarthritis; PARP: cleaved poly (ADP-ribose)
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Table 4 Immunohistochemical analysis on the tibia articular cartilages
Cell numbers (cells/mm2) Sham Control MSC PRP MP
BrdU+ 123.67 ± 24.40 7.00 ± 2.97h 49.50 ± 12.69hj 62.00 ± 16.09hj 120.33 ± 29.27jkl
IL-1β+ 5.33 ± 2.16 170.67 ± 19.94a 63.50 ± 11.64ac 41.33 ± 16.10ac 15.67 ± 10.25cdf
TNF-α+ 6.33 ± 3.14 141.00 ± 32.51a 70.33 ± 14.17ac 53.33 ± 15.24ac 28.50 ± 10.45bcdg
COX-2+ 4.00 ± 2.61 129.67 ± 44.74h 61.67 ± 13.76hj 37.50 ± 11.04hj 18.33 ± 3.93hjkl
iNOS+ 41.17 ± 17.88 243.00 ± 54.32h 124.33 ± 45.37hj 73.00 ± 10.97ij 47.60 ± 13.17ikl
Caspase-3+ 6.00 ± 3.85 102.50 ± 27.06h 43.17 ± 12.48hj 25.83 ± 5.53hj 15.33 ± 4.63hjk
PARP+ 45.67 ± 10.63 134.67 ± 38.53a 68.33 ± 17.49c 63.33 ± 19.03c 39.67 ± 12.36ceg
IFN-γ+ 7.50 ± 2.43 49.67 ± 11.40h 28.33 ± 5.79hj 22.33 ± 3.27hj 13.83 ± 3.82jkl
Values are expressed as mean ± SD of six dogs
MSC mesenchymal stem cells, PRP platelet-rich plasma, MP MSC and PRP co-treatment
ap < 0.01 as compared with sham control by LSD test
bp < 0.05 as compared with sham control by LSD test
cp < 0.01 as compared with control by LSD test
dp < 0.01 as compared with MSC treated group by LSD test
ep < 0.05 as compared with MSC treated group by LSD test
fp < 0.01 as compared with PRP treated group by LSD test
gp < 0.05 as compared with PRP treated group by LSD test
hp < 0.01 as compared with sham control by MW test
ip < 0.05 as compared with sham control by MW test
jp < 0.01 as compared with control by MW test
kp < 0.01 as compared with MSC treated group by MW test
lp < 0.01 as compared with PRP treated group by MW test
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